EverSource Wealth Advisors’s Regulus Therapeutics RGLS Stock Holding History

EverSource Wealth Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-46	Closed	-$81	–	4342
2025 Q1	$81	Sell	46 -36	-44%	-$48	﹤0.01%	3857
2024 Q4	$130	Buy	+82	New	+$126	﹤0.01%	3514

Other funds holding RGLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EverSource Wealth Advisors's RGLS Position: Q2 2025 in Review

EverSource Wealth Advisors sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 46 shares — an estimated $81 sold.

EverSource Wealth Advisors first reported a position in RGLS in Q4 2024 and held it in 2 quarters. The position peaked at $130 in Q4 2024. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

EverSource Wealth Advisors reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 46 Regulus Therapeutics shares in Q2 2025, an estimated $81.
EverSource Wealth Advisors first reported a position in Regulus Therapeutics in Q4 2024 and held it in 2 quarters.
EverSource Wealth Advisors's Regulus Therapeutics position peaked at $130 in Q4 2024.
0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on EverSource Wealth Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.